Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
-
- Yachiyo Kuwatsuka
- Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;
-
- Koichi Miyamura
- Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;
-
- Ritsuro Suzuki
- Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya;
-
- Masaharu Kasai
- Department of Hematology, Sapporo Hokuyu Hospital, Sapporo;
-
- Atsuo Maruta
- Department of Hematology, Kanagawa Cancer Center, Yokohama;
-
- Hiroyasu Ogawa
- Department of Molecular Medicine, Osaka University Graduate School of Medicine, Osaka;
-
- Ryuji Tanosaki
- Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo;
-
- Satoshi Takahashi
- Department of Hematology, Institute of Medical Science, The University of Tokyo, Tokyo;
-
- Kyuhei Koda
- Department of Hematology, Asahikawa Red Cross Hospital, Asahikawa;
-
- Kazuhiro Yago
- Department of Hematology, Shizuoka General Hospital, Shizuoka;
-
- Yoshiko Atsuta
- Department of HSCT Data Management, Nagoya University School of Medicine, Nagoya;
-
- Takashi Yoshida
- Hematology Department, Toyama Prefectural Hospital, Toyama; and
-
- Hisashi Sakamaki
- Department of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
-
- Yoshihisa Kodera
- Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya;
Description
<jats:p>We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P = .49) and inv(16) AML (74% vs 59%; P = .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P = .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.</jats:p>
Journal
-
- Blood
-
Blood 113 (9), 2096-2103, 2009-02-26
American Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1360002218954222208
-
- NII Article ID
- 10030831176
-
- ISSN
- 15280020
- 00064971
-
- Data Source
-
- Crossref
- CiNii Articles
- KAKEN